Moberg Pharma AB (publ) (MOB) - Total Liabilities
Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has total liabilities worth Skr17.04 Million SEK (≈ $1.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Moberg Pharma AB (publ)'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Moberg Pharma AB (publ) - Total Liabilities Trend (2008–2025)
This chart illustrates how Moberg Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MOB current and non-current assets.
Moberg Pharma AB (publ) Competitors by Total Liabilities
The table below lists competitors of Moberg Pharma AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PTL Enterprises Limited
NSE:PTL
|
India | Rs2.26 Billion |
|
Microtips Technology
TWO:3285
|
Taiwan | NT$697.96 Million |
|
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
|
USA | $14.61 Million |
|
Intrum Justitia AB
ST:INTRUM
|
Sweden | Skr55.88 Billion |
|
Centrepoint Alliance Ltd
AU:CAF
|
Australia | AU$24.86 Million |
|
Envoy Medical Inc.
NASDAQ:COCH
|
USA | $20.65 Million |
|
Decibel Cannabis Company Inc
V:DB
|
Canada | CA$82.85 Million |
|
Daewon Media Co. Ltd
KQ:048910
|
Korea | ₩131.59 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Moberg Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MOB equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.75 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moberg Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual total liabilities of Moberg Pharma AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.04 Million ≈ $1.83 Million |
-11.55% |
| 2024-12-31 | Skr19.27 Million ≈ $2.07 Million |
-19.73% |
| 2023-12-31 | Skr24.01 Million ≈ $2.58 Million |
-22.15% |
| 2022-12-31 | Skr30.84 Million ≈ $3.32 Million |
+83.15% |
| 2021-12-31 | Skr16.84 Million ≈ $1.81 Million |
-80.19% |
| 2020-12-31 | Skr85.00 Million ≈ $9.15 Million |
+241.22% |
| 2019-12-31 | Skr24.91 Million ≈ $2.68 Million |
-96.21% |
| 2018-12-31 | Skr657.60 Million ≈ $70.77 Million |
-1.98% |
| 2017-12-31 | Skr670.85 Million ≈ $72.19 Million |
+0.04% |
| 2016-12-31 | Skr670.55 Million ≈ $72.16 Million |
+1402.43% |
| 2015-12-31 | Skr44.63 Million ≈ $4.80 Million |
-20.26% |
| 2014-12-31 | Skr55.97 Million ≈ $6.02 Million |
-20.17% |
| 2013-12-31 | Skr70.11 Million ≈ $7.55 Million |
-31.61% |
| 2012-12-31 | Skr102.53 Million ≈ $11.03 Million |
+554.46% |
| 2011-12-31 | Skr15.67 Million ≈ $1.69 Million |
+33.96% |
| 2010-12-31 | Skr11.69 Million ≈ $1.26 Million |
+129.85% |
| 2009-12-31 | Skr5.09 Million ≈ $547.55K |
-30.83% |
| 2008-12-31 | Skr7.36 Million ≈ $791.64K |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.